Back to top
more

La Jolla Pharmaceutical Company (LJPC)

(Delayed Data from NSDQ)

$8.26 USD

8.26
455,799

+0.22 (2.74%)

Updated May 3, 2019 04:00 PM ET

After-Market: $8.27 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Scynexis (SCYX) Reports Q2 Loss, Tops Revenue Estimates

Scynexis (SCYX) delivered earnings and revenue surprises of 7.02% and 12.12%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Misses Revenue Estimates

VYNE Therapeutics Inc. (VYNE) delivered earnings and revenue surprises of 13.33% and 58%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

MediWound (MDWD) Reports Q2 Loss, Misses Revenue Estimates

MediWound (MDWD) delivered earnings and revenue surprises of -30% and 11.42%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Jazz Pharmaceuticals (JAZZ) Q2 Earnings and Revenues Beat Estimates

Jazz (JAZZ) delivered earnings and revenue surprises of 2.38% and 2.71%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

AcelRx Pharmaceuticals (ACRX) Reports Q1 Loss, Lags Revenue Estimates

AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 0% and 11.60%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Marinus Pharmaceuticals (MRNS) Reports Q1 Loss, Tops Revenue Estimates

Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of 40.23% and 548.36%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Ardelyx (ARDX) Reports Q1 Loss, Tops Revenue Estimates

Ardelyx (ARDX) delivered earnings and revenue surprises of -5% and 87.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

La Jolla Pharmaceutical (LJPC) Reports Q3 Loss, Tops Revenue Estimates

La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of -14.29% and 10.03%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

La Jolla Pharmaceutical (LJPC) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

La Jolla Pharmaceutical (LJPC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

La Jolla Pharmaceutical (LJPC) Tops Q2 Earnings and Revenue Estimates

La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of 184.62% and 34.95%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Will La Jolla Pharmaceutical (LJPC) Report Negative Q2 Earnings? What You Should Know

La Jolla Pharmaceutical (LJPC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Moving Average Crossover Alert: La Jolla Pharmaceutical (LJPC)

La Jolla Pharmaceutical (LJPC) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

La Jolla Pharmaceutical (LJPC) Misses Q1 Earnings Estimates

La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of -37.31% and 2.21%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

La Jolla Pharmaceutical (LJPC) Reports Q4 Loss, Tops Revenue Estimates

La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of 62.86% and 7.68%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

La Jolla Pharmaceutical (LJPC) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

La Jolla Pharmaceutical (LJPC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

La Jolla Pharma (LJPC) Sees Hammer Chart Pattern: Time to Buy?

La Jolla Pharmaceutical Company (LJPC) has been struggling lately, but the selling pressure may be coming to an end soon.

How La Jolla (LJPC) Stock Stands Out in a Strong Industry

La Jolla (LJPC) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

La Jolla Pharmaceutical (LJPC) Reports Q1 Loss, Lags Revenue Estimates

La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of 58.44% and -10.69%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Will La Jolla Pharmaceutical (LJPC) Report Negative Q1 Earnings? What You Should Know

La Jolla Pharmaceutical (LJPC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

La Jolla Pharmaceutical (LJPC) Reports Q4 Loss, Tops Revenue Estimates

La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of 5.10% and 0.56%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

La Jolla Pharmaceutical (LJPC) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

La Jolla Pharmaceutical (LJPC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will La Jolla Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in La Jolla Pharmaceutical.

La Jolla Pharmaceutical (LJPC) Reports Q3 Loss, Misses Revenue Estimates

La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of -0.93% and -18.05%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Will La Jolla Pharmaceutical (LJPC) Report Negative Q3 Earnings? What You Should Know

La Jolla Pharmaceutical (LJPC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

La Jolla Pharmaceutical (LJPC) Reports Q2 Loss, Lags Revenue Estimates

La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of 0.00% and -1.04%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?